Teva Pharmaceuticals
Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
DitchCarbon Score
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals's score of 55 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva Pharmaceuticals's reported carbon emissions
Teva Pharmaceuticals, headquartered in Israel, reported a total of approximately 471,063,000 kg CO2e in 2023, comprising 242,056,000 kg CO2e from Scope 1 emissions and 229,007,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its greenhouse gas emissions, aiming for a 46.2% reduction in absolute Scope 1 and 2 emissions by 2030, based on a 2019 baseline. Additionally, Teva is committed to reducing its absolute Scope 3 emissions by 25% by 2030, using 2020 as the reference year. Teva has also announced its intention to achieve net-zero emissions across its operations and value chain by 2045. This commitment aligns with industry standards and reflects a proactive approach to addressing climate change. The company’s emissions data shows a trend of decreasing emissions over the years, with total emissions of approximately 933,944,000 kg CO2e in 2017 and 647,500,000 kg CO2e in 2019, indicating a significant focus on sustainability. Overall, Teva Pharmaceuticals is actively working towards substantial emissions reductions and long-term sustainability goals, positioning itself as a responsible player in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
